. Author manuscript; available in PMC: 2013 Jul 1.

Published in final edited form as: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Apr 6;4(4):448–457. doi: 10.1002/wnan.1170

TABLE 1.

Properties of nanoparticulate MRI contrast agents approved for clinical use or under clinical evaluation.(2, 8)

Generic name (Short name)	Brand name	Relaxivity (mM ⁻¹s⁻¹) (0.47 T, 37 °C)		Size (nm)	Half-life (Dosage (μmol Fe/kg))	Target	Location (Status)
Generic name (Short name)	Brand name	r₁	r₂	Size (nm)	Half-life (Dosage (μmol Fe/kg))	Target	Location (Status)
Ferumoxide (AMI-25)	Endorem Feridex	10.1	120	80–150	2 h 30	Liver/Spleen, perfusion, angiopgraphy	US and Europe (Discontinued)
Ferumoxsil (AMI-121)	Lumirem Gastromark	N/A	N/A	300	Oral	Gastrointestinal	US and Europe
Ferumoxtran (AMI-227)	Sinerem Combidex	9.9	65	20–40	24–36 h 45	Lymph nodes, Angiopgraphy	US and Europe (Discontinued)
Ferumoxytol (AMI-228)	Feraheme	15	89	30	10–14 h 18–74	Iron replacement	US (iron therapy)
Ferrixan Ferucarbotran (SHU 555A)	Resovist Cliavist	9.7	189	60	2.4–3.6 h 8–12	Liver	Europe, Japan, and Australia
(SHU 555C)	Supravist Clariscan	10.7	38	21	6 h (40)	Angiopgraphy perfusion, angiopgrphy	Phase III complete
Feruglose (NC100150)	Supravist Clariscan	N/A	N/A	20	6 h (36)	Angiopgraphy perfusion, angiopgrphy	Phase II complete (Discontinued)